Global Biopharmaceutical Contract Manufacturing MarketsFrost & SullivanJanuary 9, 2008 57 Pages - SKU: MC1666185 |
| Countries covered: Global This Frost & Sullivan research service titled Global Biopharmaceutical Contract Manufacturing Markets provides a comprehensive overview of trends of biopharmaceutical contract manufacturing organizations (CMOs), covering mammalian and microbial cell manufacturing segments. Microbial derived biopharmaceuticals are first generation products, which is typically less complex than mammalian cell derived products. The forecasts and information provided in this research has been newly developed from coverage of CMOs and is validated with key industry participants. This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Council. Market Overview Existing First Generation Products Driving Growth Contract manufacturing of biopharmaceuticals has moved beyond being a function of "available capacity" and "cost" to being a strategic option offering flexibility, quicker time to market and lower scale up costs. Current demand is largely driven by first generation products - rh protein therapeutics and monoclonal antibodies (MAbs) targeted for cancer - the markets for most of which continue to witness double digit growth. A large number of first generation biopharmaceutical products are nearing maturity and major biopharmaceutical companies are likely to move these out to contract manufacturing organizations (CMOs) and focus on next-generation drugs, which could offer higher revenues and margins. Interestingly, the prospect of biogenerics or biosimilars is driving some "traditional" generic manufacturers to explore the possible investment into building biopharmaceutical capacity. Europe is currently leading the way in developing a pathway for the approval of biogenerics. "Biogenerics or biosimilars are likely to have a limited impact on biopharmaceutical capacity over the next 3 to 5 years as the regulatory pathway is yet to be established," notes the analyst of this research service. "However, upon market entry, biogenerics are likely to have a significant effect on pricing and cost structures of CMOs, and could drive demand for additional capacity." Mammalian Cell Manufacturing expected to Lead Growth Given the estimation that over two-thirds of biopharmaceuticals in development are mammalian cell derived, contract manufacturing for this segment is expected to grow at a much higher rate than microbial contract manufacturing. As the fast emerging market, mammalian cell manufacturing offers contract manufacturers the opportunity to gain greater share in the market through proprietary technology platforms and the opportunity for process improvement and streamlining. A significant share of mammalian cell manufacturing capacity still resides within the biopharmaceutical companies themselves and the potential for outsourcing of new products in development is significantly higher. CMOs have been effective in streamlining the manufacturing process and improving production efficiency. Overall, North America continues to remain the primary demand driver for biopharmaceutical contract manufacturing. The Asian impact on biopharmaceuticals is definitely accelerating and going forward there are likely to be a greater number of partnerships and investment being targeted at this region. "Capacity utilization, which witnessed a decline between 2003 and 2006, is beginning to rise resulting in higher revenues from existing capacity," says the analyst. "With biopharmaceutical funding beginning to rise again, smaller biopharmaceutical companies are also more likely to consider building up capacity. |
More Global Biopharmaceuticals Reports
Global Biosimilars Market Forecast to 2015 by
RNCOS
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, ...
Biosimilars: Current Situation & Future Prospects, Worldwide by
JustPharmaReports.com
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with ...
World Biological Drugs Market 2012-2022 by
Visiongain
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
Our new study ...
Global Biosimilars: A return to optimism? by
Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for ...
Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition by
Kalorama Information
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent ...
See all reports like this >>
Related Markets
Biopharmaceuticals Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Biologics Market in Brazil
- Global Biosimilars Market Forecast to 2015
- Biosimilars: Current Situation & Future Prospects, Worldwide
